Tanzania Pharma Manufacturing Equipment Guide (2026)

Tanzania imported about USD 295.3 million of pharmaceutical products in 2024 and local plants still cover only 10 to 20% of demand. A November 2025 government strategy targets 60% local supply by 2035 and ten new factories. For equipment suppliers, that gap is the procurement opportunity: tablet presses, blister lines, sterile fill-finish, and QC labs all sourced abroad.

The procurement gap behind the local-manufacturing push

Tanzania has been buying its medicines, not building them. The country spent more than USD 1.5 billion importing pharmaceutical products over the past five years, with annual imports running USD 329.9 million (2021), USD 340.4 million (2022), USD 286.2 million (2023), USD 295.3 million (2024), and a projected USD 269.9 million for the year ending September 2025, according to TanzaniaInvest reporting on the Ministry of Health directive. Local producers supply only 10 to 20% of national demand, per The Citizen, leaving up to 80% imported.

On 24 November 2025, the Ministry of Health issued a directive launching a national strategy to expand local manufacturing of medicines and health products. Health Minister Mohamed Mchengerwa set hard deadlines: form a coordinating task force within 7 days, compile a list of every investor who has expressed interest since 2015 within 15 days, and publish official investment opportunities through government platforms and Special Economic Zones within 21 days. The plan names ten new factories producing ARVs, tablets, injectables, drips, and reagents. The long-term policy target is 60% local supply by 2035.

That is a buyer-side signal, not a competitor threat. Every one of those ten factories has to be tooled. Tanzania does not build tablet presses, blister machines, autoclaves, or water-for-injection skids. Those come from OEMs in Germany, Italy, India, China, and Korea. A directive that says “build ten plants” is, for an equipment maker, a directive that says “ten plants are about to issue RFQs.”

Procurement opportunity by sub-segment

A pharmaceutical plant is not one purchase. It is a stack of process lines, each quoted separately, often to different vendors. Here is where the Tanzanian spend lands.

Tablet presses and solid-dose lines. Oral solids are the backbone of the local sector. Rotary tablet presses, high-shear and fluid-bed granulators, coating pans, and de-dusters are the first kit any greenfield oral-solids plant buys. Shelys and Zenufa already run solid-dose lines; the ten planned factories will pull more.

Granulation. Wet granulation (high-shear mixers plus fluid-bed dryers) and dry granulation (roller compactors) feed the tablet presses. This is a discrete RFQ line, frequently sourced from a different OEM than the press itself.

Blister and sachet packaging. Tanzania Bureau of Standards (TBS) certification and TMDA marketing authorisation both hinge on compliant primary packaging. Blister thermoformers, sachet form-fill-seal machines, cartoners, and serialisation/track-and-trace coders are high-frequency RFQ items because packaging upgrades happen independently of process retooling. The country pillar already flags TBS-certified packaging lines as a recurring procurement theme. See our Tanzania industrial and procurement guide for the cross-sector TBS context.

Sterile and fill-finish. Kairuki Pharmaceuticals runs IV-fluid production, and the government’s named priority list includes injectables and drips. Sterile manufacturing is the most equipment-intensive segment: vial and ampoule filling lines, isolators and RABS, lyophilisers, terminal sterilisation autoclaves, and depyrogenation tunnels. This is where the highest-ticket import RFQs sit.

Water for injection (WFI) and clean utilities. No sterile or even non-sterile GMP plant clears a TMDA inspection without validated water. Multi-effect or vapour-compression WFI stills, pure-steam generators, purified-water RO/EDI skids, and clean-in-place systems are mandatory infrastructure. WFI generation is a specialist niche where European and Indian OEMs dominate.

QC laboratory instrumentation. GMP requires in-house quality control: HPLC and UHPLC systems, dissolution testers, FTIR and UV-Vis spectrophotometers, stability chambers, and microbiology incubators. TMDA’s facilitative inspections check that the lab can actually release product. QC kit is a recurring spend, not a one-off.

Named buyers and end-users

The RFQ issuers in Tanzanian pharma are a mix of established local manufacturers, the central medical buyer, and the incoming greenfield investors.

Established manufacturers. The Tanzania Medicines and Medical Devices Authority (TMDA) lists 18 operational facilities and counts 11 dedicated to human medicines. The named GMP-track producers include Shelys Pharmaceuticals (Dar es Salaam, the largest local manufacturer, majority-owned by Aspen Pharmacare of South Africa), Zenufa Laboratories (Dar es Salaam, oral solids and liquids), Tanzania Pharmaceutical Industries (TPI) with its ARV line, Keko Pharmaceuticals, and Kairuki Pharmaceuticals (Pwani, IV fluids). These are the buyers running active upgrade and capacity-expansion RFQs today.

Medical Stores Department (MSD). MSD is the government’s central procurement and distribution agency for medicines and medical supplies. While MSD buys finished product rather than plant equipment, its tenders set the demand signal that drives local capacity investment, and its preference for locally manufactured supply (a stated procurement-pricing incentive under the strategy) is the commercial logic any equipment buyer is responding to.

Greenfield investors. The 15-day directive to compile every interested investor since 2015, plus the 30-day consolidated investor meeting, means a defined pool of named buyers is being assembled by the government itself. The Theon Pharmaceutical manufacturing facility is one example already in the public record. These are the cleanest equipment RFQs because they tool from zero.

FX, letters of credit, and payment mechanics for pharma kit

Pharmaceutical equipment is mid-ticket capital goods: a tablet-press line or a WFI skid runs in the low-to-mid six figures, a full sterile fill-finish suite higher. That puts most deals squarely in letter-of-credit territory.

The Bank of Tanzania moved the shilling to a floating regime in November 2024 under the IMF program, and the TZS appreciated roughly 9.5% against the USD over the following year on the back of record gold and cashew receipts. FX availability has improved, but USD liquidity still tightens in high-import quarters, so a confirmed LC is the safe default. The major confirming banks are CRDB, NMB, NBC, Stanbic, and Standard Chartered Tanzania, with Tier 1 European or Gulf confirmation standard above USD 5 million.

Pharma carries one payment wrinkle other sectors do not. TMDA waives import charges on raw materials for registered domestic manufacturers and offers reduced or waived registration, inspection, and retention fees. SEZ-located plants get VAT and duty exemption on equipment plus a 10-year corporate-tax holiday. Quote DDP where you can, and check the buyer’s TMDA and SEZ status before pricing duty into the deal, because a registered manufacturer often imports your machine duty-free. Euro-denominated quotes are accepted and frequently preferred for European-origin process equipment.

EPC contractors and turnkey integrators

Most Tanzanian pharma plants are not assembled by the buyer’s own engineering team. They go through pharma-engineering integrators who bundle process equipment, cleanroom build, HVAC, and validation into a turnkey GMP package. For a single-line equipment OEM, the practical question is whether you sell through one of these integrators as a named sub-vendor or around them by bidding the process island directly to the plant owner.

Indian turnkey pharma-EPC houses are the most active in East Africa, given India’s deep generics-manufacturing base and EXIM Bank Line of Credit financing. European cleanroom and process-engineering firms compete on the sterile and WFI end where GMP scrutiny is highest. Component suppliers (presses, fillers, autoclaves, HPLC) typically land on the integrator’s vendor list rather than the owner’s, so the integrator relationship is the channel that matters. Greenfield projects on the government’s investor list are the moments where vendor lists are still open.

Tender platforms and procurement entry points

Two entry points cover almost all of it. TANePS, the Tanzania National e-Procurement System run under the Public Procurement Regulatory Authority, is where parastatal and MSD-adjacent tenders surface; register as a bidder and filter by health-products categories. The second is TMDA itself, the Tanzania Medicines and Medical Devices Authority (successor to the former TFDA), which governs premises registration, GMP inspection, and marketing authorisation. No equipment sale closes without the buyer clearing TMDA’s premises and GMP gates, so your machine has to be specified to pass them. TMDA has cut product-registration timelines from 180 to 60 days, which compresses the whole project clock and the equipment-procurement window with it.

Regionally, the East African Community Medicines Regulatory Harmonization (EAC-MRH) programme, running since 2012 across a bloc of roughly 290 million people, lets a GMP inspection and a product dossier be assessed jointly across partner states. For an equipment buyer that means a Tanzanian plant tooled to EAC-harmonised GMP can sell into Kenya, Uganda, Rwanda, Burundi, and the DRC, which raises the capacity (and therefore the equipment spec) a Tanzanian manufacturer will justify. Quote for the regional volume, not just the domestic one.

Dying conventional channels

The old ways of reaching Tanzanian pharma buyers are getting expensive relative to what they return.

Trade fairs. The Dar es Salaam International Trade Fair (DITF / Saba Saba) is a national institution but skews consumer-goods, and pharma procurement teams rarely work it for capital equipment. Regional pharma expos like East Africa’s medical and lab-equipment shows pull some traffic, but for a process-equipment OEM the fully loaded cost per qualified lead (booth, freight, travel, follow-up) typically lands between USD 400 and USD 900, with conversion to a real RFQ well under 5%.

Field representatives. A Dar-based technical sales rep with pharma-equipment knowledge runs USD 5,500 to USD 11,000 per month all-in. At three to six qualified leads a month, that is USD 900 to USD 3,700 per qualified lead, and the unit economics only clear above several million euros of annual Tanzanian revenue.

Distributor and agent lock-in. Legacy medical-equipment trading houses carry pharma machinery inside broad catalogues, take 15 to 30% margin, and rarely run active outbound. Niche process equipment (WFI skids, isolators, serialisation) sits invisible inside those catalogues, which is exactly where a direct OEM relationship wins on engineering fit.

Print and trade-magazine advertising. Tanzanian pharma procurement and project engineers find vendors through TMDA and TANePS notifications, peer engineers, and English-language search, not print.

FAQ

How big is Tanzania’s pharmaceutical equipment opportunity?

Tanzania imported about USD 295.3 million of pharmaceutical products in 2024 and aims to lift local supply from 10 to 20% today to 60% by 2035, with ten new factories planned. Each plant must import its process and packaging equipment, making the equipment opportunity a function of that local-manufacturing ramp.

What regulator approves pharmaceutical plants in Tanzania?

The Tanzania Medicines and Medical Devices Authority (TMDA), successor to the former TFDA, governs premises registration, GMP inspection, and marketing authorisation. Equipment must be specified to pass TMDA’s GMP and validation checks. TMDA has cut product-registration timelines from 180 days to 60 days.

Can a Tanzanian pharma plant sell into the wider region?

Yes. The East African Community Medicines Regulatory Harmonization programme allows joint GMP inspections and dossier assessment across EAC partner states, a market of roughly 290 million people. A Tanzanian plant built to harmonised GMP can supply Kenya, Uganda, Rwanda, Burundi, and the DRC, which justifies larger capacity and equipment specs.

How do pharma equipment deals get paid in Tanzania?

Through confirmed letters of credit for mid-six-figure-and-up tickets, with CRDB, NMB, Stanbic, or Standard Chartered Tanzania confirming and a Tier 1 bank co-confirming above USD 5 million. Registered domestic manufacturers and SEZ-located plants often import equipment duty-free, so check the buyer’s TMDA and SEZ status before pricing duty.

Who are the main local pharmaceutical manufacturers?

TMDA lists 18 operational facilities, 11 producing human medicines. The largest is Shelys Pharmaceuticals (majority-owned by Aspen), alongside Zenufa Laboratories, Tanzania Pharmaceutical Industries (TPI), Keko Pharmaceuticals, and Kairuki Pharmaceuticals for IV fluids. These plus the incoming greenfield investors are the RFQ issuers.

Where to go next

This guide maps the sector. The sharp RFQ detail lives one layer down, at the equipment line itself: tablet presses and granulation, blister and sachet packaging, sterile fill-finish, water-for-injection, and QC lab instrumentation. As we publish those Tanzania equipment-level guides, they will sit alongside this page.

For the cross-sector procurement mechanics (TANePS registration, TBS certification, LC structures, customs), start with the Tanzania industrial and procurement guide. When you want to position your specific equipment against Tanzania’s named pharma buyers and the incoming greenfield projects, contact us for a procurement-side conversation, or reach Burak directly at burak@papaverai.com. We map the buyer, you bring the engineering.